2018
DOI: 10.1371/journal.pone.0194236
|View full text |Cite
|
Sign up to set email alerts
|

The current evidence base for the feasibility of 48-hour continuous subcutaneous infusions (CSCIs): A systematically-structured review

Abstract: BackgroundA continuous subcutaneous infusion (CSCI) is an effective method of multiple drug administration commonly encountered in end of life care when the oral route is compromised. At present, current practice is to limit syringe driver infusion time to a maximum of 24 hours as dictated by available chemical stability data. However, the ability to deliver prescribed medication by a CSCI over 48 hours may have numerous benefits in both patient care and health service resource utilisation.AimTo examine and pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
2
0
1

Year Published

2020
2020
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 31 publications
0
2
0
1
Order By: Relevance
“…L'obiettivo della revisione sistematica di Baker et al [23] era di cercare evidenze scientifiche sulla stabilità di soluzioni farmacologiche oltre le 24 ore. Sono stati inclusi 32 studi sperimentali riportanti compatibilità e stabilità di 32 combinazioni di farmaci. Quelli più frequentemente inclusi negli studi erano Aloperidolo, Morfina, Midazolam e Desametasone.…”
Section: Combinazioni DI Farmaciunclassified
“…L'obiettivo della revisione sistematica di Baker et al [23] era di cercare evidenze scientifiche sulla stabilità di soluzioni farmacologiche oltre le 24 ore. Sono stati inclusi 32 studi sperimentali riportanti compatibilità e stabilità di 32 combinazioni di farmaci. Quelli più frequentemente inclusi negli studi erano Aloperidolo, Morfina, Midazolam e Desametasone.…”
Section: Combinazioni DI Farmaciunclassified
“…CSCI applications further minimize pricking events which improves the compliance among patients and their relatives [5]. However, there are limited data about the chemical compatibility over at least 24 h of application [6]. [5].…”
Section: Introductionmentioning
confidence: 99%
“…[5]. However, there are limited data about the chemical compatibility over at least 24 h of application [6].…”
Section: Introductionmentioning
confidence: 99%